A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
AffiliationBaylor College of Medicine, Houston, Texas, USA.
MetadataShow full item record
AbstractThis article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.
CitationA roundtable discussion of aromatase inhibitors as therapy for breast cancer., 9 (3):213-22 Breast J
JournalThe Breast Journal